[go: up one dir, main page]

CY1110994T1 - Il-7 φαρμακευτικη ουσια, συνθεση που περιεχει il-7 παρασκευη και χρησεις αυτης - Google Patents

Il-7 φαρμακευτικη ουσια, συνθεση που περιεχει il-7 παρασκευη και χρησεις αυτης

Info

Publication number
CY1110994T1
CY1110994T1 CY20101101165T CY101101165T CY1110994T1 CY 1110994 T1 CY1110994 T1 CY 1110994T1 CY 20101101165 T CY20101101165 T CY 20101101165T CY 101101165 T CY101101165 T CY 101101165T CY 1110994 T1 CY1110994 T1 CY 1110994T1
Authority
CY
Cyprus
Prior art keywords
product
drug
preparation
well
substances
Prior art date
Application number
CY20101101165T
Other languages
English (en)
Inventor
Michel Christian Morre
Brigitte Assouline
Pierre Cortez
Anne Gregoire
Original Assignee
Cytheris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytheris filed Critical Cytheris
Publication of CY1110994T1 publication Critical patent/CY1110994T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά γενικά τους τομείς της ανοσολογίας και της μοριακής βιολογίας. Η εφεύρεση αποκαλύπτει ειδικότερα νέες και βελτιωμένες φαρμακευτικές ουσίες ιντερλευκίνης-7, οι οποίες αντιστοιχούν σε ειδικά ανοσοδραστικά αντισώματα, καθώς επίσης και συνθέσεις, οι οποίες περιέχουν αυτές, την παρασκευή αυτών και τις χρήσεις αυτών. Η εφεύρεση επίσης αποκαλύπτει μεθόδους για τον χαρακτηρισμό, του προφίλ ακαθαρσίας μιας r-hlL-7 φαρμακευτικής ουσίας που χρησιμοποιείται για θεραπευτικό σκοπό, καθώς επίσης και βελτιστοποιημένες νουκλεοτιδικές αλληλουχίες, που κωδικεύουν IL-7 θηλαστικών, ανασυνδυασμένους φορείς έκφρασης και μεθόδους για την παρασκευή και τον καθαρισμό των αναφερθέντων πολυπεπτιδίων. Η παρούσα εφεύρεση προέρχεται από την απροσδόκητη ανακάλυψη ότι η δραστικότητα του ανασυνδυασμένου IL-7 σε βάθος χρόνου, εκφράζεται ως επί το πλείστον από ένα ειδικό διαμορφομερές και ότι άλλα διαμορφομερή, ενδεχομένως σχετικές προς το προϊόν ουσίες, σχετικές προς το προϊόν ακαθαρσίες και σχετικές προς την μέθοδο ακαθαρσίες, οι οποίες κανονικά θα συμπεριλαμβάνονταν εις την προδιαγραφή της φαρμακευτικής ουσίας και/ή του φαρμακευτικού προϊόντος, παρότι βιοδραστικές, πρέπει να ελαχιστοποιούνται αυστηρά, γιατί είναι ικανές να πυροδοτήσουν μια ανοσοαντίδραση εναντίον του επιθυμητού μορίου IL-7.
CY20101101165T 2002-08-08 2010-12-17 Il-7 φαρμακευτικη ουσια, συνθεση που περιεχει il-7 παρασκευη και χρησεις αυτης CY1110994T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02291996A EP1391513A1 (en) 2002-08-08 2002-08-08 IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
US47588103P 2003-06-05 2003-06-05
EP03792262A EP1527179B1 (en) 2002-08-08 2003-08-06 Il-7 drug substance, il- 7 comprising composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
CY1110994T1 true CY1110994T1 (el) 2015-06-11

Family

ID=30775891

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101165T CY1110994T1 (el) 2002-08-08 2010-12-17 Il-7 φαρμακευτικη ουσια, συνθεση που περιεχει il-7 παρασκευη και χρησεις αυτης

Country Status (17)

Country Link
US (1) US7585947B2 (el)
EP (2) EP1391513A1 (el)
JP (3) JP2005534339A (el)
AT (1) ATE482273T1 (el)
AU (1) AU2003250216B2 (el)
CA (1) CA2494974C (el)
CY (1) CY1110994T1 (el)
DE (1) DE60334301D1 (el)
DK (1) DK1527179T3 (el)
ES (1) ES2353006T3 (el)
IL (1) IL166543A (el)
NO (1) NO332305B1 (el)
PL (1) PL213710B1 (el)
PT (1) PT1527179E (el)
SI (1) SI1527179T1 (el)
WO (1) WO2004018681A2 (el)
ZA (1) ZA200501914B (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
ES2305886T3 (es) * 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
WO2007022623A1 (en) * 2005-08-23 2007-03-01 National Research Council Of Canada Regulation of heterologous recombinant protein expression in methylotrophic and methanotrophic bacteria
CA2655392A1 (en) * 2006-05-31 2007-12-06 The Regents Of The University Of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
NO346530B1 (no) 2006-09-28 2022-09-26 Merck Sharp & Dohme Anvendelser av pegylert interleukin-10 (PEG-IL-10) for å forebygge metastaser av kreft eller tumor i lungene.
US9266937B2 (en) 2010-12-10 2016-02-23 University Of Central Florida Research Foundation, Inc. Compositions comprising IL-7 receptor ligands
MX2014001355A (es) 2011-08-03 2014-11-21 Cytheris Inmunoterapia contra el vhc.
JP6126684B2 (ja) * 2012-04-23 2017-05-10 バハラ バイオテック インターナショナル リミテッド 新規なロタウイルスワクチン組成物及び同組成物を調製する方法
RU2562169C2 (ru) * 2012-10-29 2015-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Штамм культивируемых клеток cho-il7/13 - продуцент интерлейкина-7 человека
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
US20180028593A1 (en) 2014-03-21 2018-02-01 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MA41957A (fr) * 2015-03-11 2018-02-28 Nektar Therapeutics Conjugués d'une fraction d'il-7 et d'un polymère
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
JP2018518955A (ja) * 2015-06-11 2018-07-19 ジェネクシン・インコーポレイテッドＧｅｎｅｘｉｎｅ， Ｉｎｃ． 改変されたインターロイキン−７タンパク質およびその使用
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
RU2615447C1 (ru) * 2015-11-13 2017-04-04 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Синтетическая ДНК, кодирующая интерлейкин-7 человека, содержащий ее экспрессионный вектор (варианты), штамм-продуцент интерлейкина-7 человека и способ получения интерлейкина-7 человека
US11357827B2 (en) 2015-12-04 2022-06-14 Genexine, Inc. Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein
CN108697765A (zh) * 2015-12-04 2018-10-23 格纳西尼有限公司 用于预防或治疗人乳头瘤病毒引起的疾病的含有免疫球蛋白fc融合il-7融合蛋白的药物组合物
WO2018156649A1 (en) * 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
CA3123338A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
KR102402276B1 (ko) * 2019-11-15 2022-05-26 주식회사 제넥신 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
KR20220137630A (ko) 2020-02-05 2022-10-12 워싱턴 유니버시티 Il-7 단백질과 car-보유 면역 세포의 조합물로 고형 종양을 치료하는 방법
KR20230098201A (ko) 2020-10-26 2023-07-03 네오이뮨텍, 인코퍼레이티드 줄기 세포 동원의 유도 방법
WO2022094475A1 (en) 2020-11-02 2022-05-05 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
JP2023549112A (ja) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
EP4251186A4 (en) * 2020-11-25 2024-11-06 Jecho Laboratories, Inc. IL-7 HYBRID PROTEIN AND RELATED METHODS
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
CN117050178B (zh) * 2023-10-13 2024-01-12 北京百普赛斯生物科技股份有限公司 特异性检测il-7的抗体及应用
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
ZA887773B (en) * 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5459058A (en) * 1991-03-28 1995-10-17 Benjamin Rich Cell culture system
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
WO1994022473A1 (en) * 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
EP1012184B1 (en) * 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
EP2314696A1 (en) * 1998-09-21 2011-04-27 Schering Corporation Therapeutic uses of human Interleukin-B50 antagonist.
US6749847B2 (en) * 2000-03-30 2004-06-15 The University Of Connecticut Hybrid cytokine of IL-7 and β-chain of hepatocyte growth factor
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses

Also Published As

Publication number Publication date
JP2014147396A (ja) 2014-08-21
JP2010115203A (ja) 2010-05-27
EP1391513A1 (en) 2004-02-25
DK1527179T3 (da) 2011-01-03
ATE482273T1 (de) 2010-10-15
AU2003250216B2 (en) 2010-08-05
ZA200501914B (en) 2005-11-30
US7585947B2 (en) 2009-09-08
ES2353006T3 (es) 2011-02-24
SI1527179T1 (sl) 2011-04-29
WO2004018681A2 (en) 2004-03-04
JP5980467B2 (ja) 2016-08-31
PL373606A1 (en) 2005-09-05
PT1527179E (pt) 2010-12-07
IL166543A0 (en) 2006-01-15
IL166543A (en) 2012-02-29
JP2005534339A (ja) 2005-11-17
WO2004018681A3 (en) 2004-04-01
EP1527179B1 (en) 2010-09-22
DE60334301D1 (de) 2010-11-04
CA2494974A1 (en) 2004-03-04
AU2003250216A1 (en) 2004-03-11
EP1527179A2 (en) 2005-05-04
NO332305B1 (no) 2012-08-20
US20050249701A1 (en) 2005-11-10
NO20050355L (no) 2005-05-06
HK1075465A1 (en) 2005-12-16
CA2494974C (en) 2014-07-29
PL213710B1 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
CY1110994T1 (el) Il-7 φαρμακευτικη ουσια, συνθεση που περιεχει il-7 παρασκευη και χρησεις αυτης
Tam et al. Membranolytic selectivity of cystine‐stabilized cyclic protegrins
CN101434650B (zh) 法氏囊五肽、其衍生肽及其应用
DK2027152T3 (da) Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
IL172613A (en) Antibodies that bind at least two different human inhibitory kir gene products, hybridomas producing said antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies and use thereof for the manufacture of a medicament to potentiate nk cell activity
Xu et al. Isolation, structure determination, and synthesis of galaxamide, a rare cytotoxic cyclic pentapeptide from a marine algae Galaxaura filamentosa
Jalil et al. Multivalent, soluble nano-self peptides increase phagocytosis of antibody-opsonized targets while suppressing “self” signaling
IL206157A (en) Pancreatic elastase protein of type 1, a nucleic acid molecule encoded by a protein
EP1252183B1 (en) Method for reducing the immunogenicity of staphylokinase by elimination of t-cell epitopes
FR2726472B1 (fr) Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
Meli et al. Recombinant human prolactin induces protection against Salmonella typhimurium infection in the mouse: role of nitric oxide
KR20150040594A (ko) 여드름 개선 효과를 보이는 프로태티아마이신 항생펩타이드 유도체 및 그 용도
EP3647320A1 (en) Acetylcholine receptor-binding peptide
DE3751646D1 (de) Rekombinantes Produkt
JPH03503897A (ja) ひとｇｍ‐ｃｓｆ変異形類
ATE184287T1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
DK1947175T3 (da) Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf
Guichard β‐Peptides, γ‐Peptides and Isosteric Backbones: New Scaffolds with Controlled Shapes for Mimicking Protein Secondary Structure Elements
CN106478811B (zh) 虎纹蛙蛋白酶抑制肽及其基因和在制药中的应用
AU2015240516B2 (en) Artificially activated peptides
Li et al. Expression, purification and characterization of a novel soluble human thymosin alpha1 concatemer exhibited a stronger stimulation on mice lymphocytes proliferation and higher anti-tumor activity
AU676842B2 (en) Neutrophil stimulating peptides
Musavi Motlagh et al. Improving purification of coagulation F IX using heparin affinity chromatography and its comparison with ion exchange chromatography
Shingarova et al. Novel mutants of human tumor necrosis factor with dominant-negative properties
HU208156B (en) Process for producing /n-(gamma-glutamyl)-glycyl/-alanine derivatives and pharmaceutical compositions comprising same